이식 후 당뇨병 예방을위한 semaglutide (SPOT-DM)
The study aims to determine the short-term efficacy, mechanisms and safety of 24 weeks of semaglutide therapy in 37 KTR at risk of post-transplant diabetes mellitus (PTDM).
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
A kidney transplant is the best treatment for people living with kidney failure as it allows people to live longer with a better quality of life. However, one in four kidney transplant recipients will develop diabetes after transplant. This is largely due to the medications that must be used to prevent rejection of the transplant. Kidney transplant recipients who get diabetes after transplant are up to three times more likely to have heart disease and die prematurely. To date, there are no treatments to prevent the development of diabetes after kidney transplant. Semaglutide is a drug that is commonly used to treat diabetes and obesity. The investigators believe that semaglutide is a safe and effective drug which can prevent the development of diabetes in kidney transplant recipients. Therefore, the investigators are conducting a study where kidney transplant recipients who are at increased risk of developing diabetes after transplant will receive semaglutide for 24 weeks after their transplant. The study will determine whether semaglutide is effective in decreasing blood sugar levels and the rate of diabetes. The investigators will also study other important markers of health including body weight and cholesterol levels as well as liver, kidney and heart function. Diabetes after transplant is a common problem, and preventing it is extremely important to allowing kidney transplant recipients to live longer and better lives. The results of this study will allow the investigators to determine if semaglutide is a safe and effective option for the prevention of diabetes in kidney transplant recipients.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 2 단계
- 3단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Cheng Xu
- 전화번호: 8508 416-340-4800
- 이메일: cheng.xu@uhn.ca
연구 장소
-
-
British Columbia
-
Vancouver, British Columbia, 캐나다, V6Z 1Y6
- St. Paul's Hospital
-
연락하다:
- Vikas S Srinivasan, MD PhD FRCPC
- 전화번호: 604-806-8970
- 이메일: vikas.sridhar@phc.ca
-
-
Ontario
-
Toronto, Ontario, 캐나다, M5G 2N2
- Toronto General Hospital
-
연락하다:
- Cheng Xu
- 전화번호: 8508 416-340-4800
- 이메일: cheng.xu@uhn.ca
-
수석 연구원:
- Sunita Singh, MD MSc FRCPC
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Signed and dated written informed consent.
-
Adult (≥18 years) recipients of a living or deceased donor kidney transplant
-
Between 4- and 12-weeks post kidney transplant
-
Stable kidney function defined as an eGFR > 30 ml/min/1.73m2 (CKD-EPI)
-
At risk for PTDM at the time of transplant based on the following criteria:
- BMI ≥ 25 kg/m2, or
- Fasting plasma glucose 6.1-6.9 mmol/L (impaired fasting glucose), or
- 2hr OGTT plasma glucose 7.8-11.0 (impaired glucose tolerance), or
- HbA1C 5.5-6.4% (at risk for DM or prediabetes).
Exclusion Criteria:
- Established diagnosis of type 1 or type 2 DM as per Diabetes Canada (including the need for glucose-lowering therapy for hyperglycemia at the time of screening)
- Kidney-Pancreas transplant recipient
- Acute coronary syndrome, transient ischemic attack or stroke within 30 days prior to screening
- History of pancreatitis
- Personal or family history of medullary thyroid cancer or MEN2B
- Women who are pregnant, nursing or plan on becoming pregnant whilst in the trial
- Use of GLP1RA in the 30 days prior to screening
- Contraindication to MRI (applicable only to those undergoing the optional MRI assessments)
- With known or suspected hypersensitivity to semaglutide or related products
- Patient not able to understand and comply with study requirements, based on Investigator's judgment.
- Any other clinical condition that, based on Investigator's judgement, would jeopardize patient safety during trial participation or would affect the study outcom
- History of glucose-galactose malabsorption syndrome
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Semaglutide
Patients will be up-titrated as tolerated starting at 0.25 mg subcutaneous semaglutide once weekly for 4 weeks, followed by 0.5 mg, 1.0 mg, and 1.7 mg semaglutide for 4 weeks each, and then 2.4 mg subcutaneous semaglutide once weekly for 8 weeks. Semaglutide can be down-titrated by the investigator to lower doses or up-titrated at slower rates if not tolerated by the participant. |
Subcutaneous semaglutide 0.25mg for 4 weeks. Subcutaneous semaglutide 0.5mg for 4 weeks. Subcutaneous semaglutide 1.0 mg for 4 weeks. Subcutaneous semaglutide 1.7 mg for 4 weeks Subcutaneous semaglutide 2.4 mg for 8 weeks |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
2-hour OGTT
기간: 24 weeks
|
The primary outcome of this study is the change in plasma glucose at 120 minutes following a 75g oral glucose challenge (2-hour OGTT) at 24 weeks. The 2-hour OGTT was selected as the primarily outcome in this study for the following reasons: 1) In selecting a surrogate outcome for PTDM in KTR, there are limitations to HbA1c and fasting glucose in this population; 2) The 2-hour OGTT is the recommended test for the diagnosis of PTDM in KTR and 3) The use of OGTT has been used in other PTDM prevention studies. |
24 weeks
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
수축기 혈압
기간: 24주
|
24주
|
|
|
체중의 변화
기간: 24주
|
24주
|
|
|
허리둘레의 변화
기간: 24주
|
24주
|
|
|
HbA1c의 변화
기간: 24주
|
24주
|
|
|
공복 혈당의 변화
기간: 24 주
|
24 주
|
|
|
혈청 인슐린의 변화
기간: 24 주
|
24 주
|
|
|
공복 지질 프로파일의 변화
기간: 24 주
|
24 주
|
|
|
이완기 혈압
기간: 24 주
|
24 주
|
|
|
평균 동맥압
기간: 24 주
|
24 주
|
|
|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
기간: 24 weeks
|
: The side effects of GLP-1RA have been well described and will be assessed at each study visit. Adverse events include AKI, hypoglycemia, volume depletion, GI intolerance, amputations, pancreatitis, hepatobiliary complications and injection site or allergic reactions, infectious complications (any source), and malignancy. Episodes of biopsy-proven acute rejection (as defined by the Banff criteria), death-censored graft failure (defined as the need for initiation of chronic dialysis or re-transplantation) or death with graft function (defined as death with a functioning allograft) will also be collected. Kidney transplantation assures complete denervation of the transplanted kidney and the renal vasoconstrictive response in the setting of intravascular volume depletion is diminished in KTR. Therefore, frequent monitoring for adverse events has been integrated in our study design, occurring on 10 separate occasions, to capture these adverse events should they occur. |
24 weeks
|
|
Estimated GFR
기간: 24 weeks
|
Calculated by CKD-EPI 2021 equation |
24 weeks
|
|
GFR
기간: 24 weeks
|
Measured using 24-urine collection for creatinine, standardized per 1.73m2 body surface area. And estimated using CKD-EPI 2021 equation. |
24 weeks
|
|
Albuminuria
기간: 24 weeks
|
measuring urine albumin excretion from a 24-hour urine collection |
24 weeks
|
|
Natriuresis
기간: 24 weeks
|
Assessed with a 24-hour urine collection for sodium excretion |
24 weeks
|
|
Percentage of body fat
기간: 24 weeks
|
Bioimpedance analysis |
24 weeks
|
|
Change in liver enzymes
기간: 24 weeks
|
ALT and AST |
24 weeks
|
|
Change in fibrosis level
기간: 24 weeks
|
Transient elastography |
24 weeks
|
|
Change in steatosis level
기간: 24 weeks
|
Transient elastography |
24 weeks
|
|
Percentage of extracellular fluid
기간: 24 weeks
|
Bioimpedance analysis |
24 weeks
|
기타 결과 측정
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in kidney oxygenation (R2*)
기간: 24 weeks
|
Assessed via multiparametric kidney MRI in an optional cohort. |
24 weeks
|
|
Change in kidney fibrosis (ADC)
기간: 24 weeks
|
Assessed via multiparametric kidney MRI in an optional cohort. |
24 weeks
|
|
Change in kidney perfusion
기간: 24 weeks
|
Assessed via multiparametric kidney MRI in an optional cohort. |
24 weeks
|
|
Change in kidney volume
기간: 24 weeks
|
Assessed via multiparametric kidney MRI in an optional cohort. |
24 weeks
|
|
Change in kidney inflammation (T1)
기간: 24 weeks
|
Assessed via multiparametric kidney MRI in an optional cohort. |
24 weeks
|
공동 작업자 및 조사자
수사관
수사관
- 수석 연구원: Sunita Singh, MD MSc FRCPC, University Health Network, Toronto General Hospital
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- 25-5093
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .